Related Experiment Videos
Lipids and atherosclerosis: clinical management of hypercholesterolaemia
1Alfred and Baker Medical Unit, Baker Medical Research Institute and Heart Centre, Alfred Hospital, Commercial Rd, Prahran 3181, Australia. j.chin@alfred.org.au
Insights
High cholesterol (hypercholesterolaemia) is a key driver of atherosclerosis and heart disease. Effective lipid-lowering therapies, particularly statins, significantly reduce cardiac events and mortality in high-risk patients.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Hypercholesterolaemia is a primary risk factor for atherosclerosis, the underlying cause of most ischaemic heart disease (IHD).
- Lipid management is crucial for preventing cardiovascular events.
Purpose of the Study:
- To review the pathophysiology of lipids in humans.
- To discuss current and emerging lipid-lowering therapies.
- To evaluate the impact of these therapies on cardiovascular outcomes.
Main Methods:
- Literature review of human lipid pathophysiology.
- Analysis of clinical data on lipid-lowering treatments.
- Discussion of the efficacy and tolerability of various drug classes.
Main Results:
- Lipid-lowering therapy, especially statins (HMG CoA reductase inhibitors), has revolutionized hypercholesterolaemia management.
- Statins demonstrate significant efficacy and good tolerability, reducing cardiac events and mortality in patients with a history of myocardial infarction or unstable angina.
- Other therapies like fibrates and bile acid resins are also discussed.
Conclusions:
- Statins have transformed the clinical management of hypercholesterolaemia due to their efficacy and tolerability.
- Future therapeutic impact may come from compounds that increase HDL-cholesterol while lowering LDL-cholesterol.
- A trend towards naturally occurring compounds like plant stanols and phytoestrogens is anticipated.
Abstract:
Hypercholesterolaemia is a major risk factor for the development of atherosclerosis which, in turn, underlies most ischaemic heart disease (IHD). This review deals briefly with the pathophysiology of lipids in humans and follows with a discussion of current lipid-lowering therapies. In those patients with a history of myocardial infarction (MI) or unstable angina, appropriate lipid-lowering therapy has been convincingly shown to reduce not only cardiac events but also overall mortality. The advent of the HMG CoA reductase inhibitors in the late 1980s has had a revolutionary impact in the clinical management of hypercholesterolaemia, not only because of their efficacy but especially because they are well-tolerated. The use of other treatments such as the fibrates and bile acid resins are also discussed. Given the successful use of the statins, it is felt that an emergence of a different class of LDL-cholesterol lowering compound is unlikely in the near future and rather that compounds which can increase HDL-cholesterol while lowering LDL will be of greater impact. There may also be a shifting trend towards such naturally occurring compounds as plant stanols and phytoestrogens.